Details of the Drug

General Information of Drug (ID: DMRMS0L)

Drug Name
Morphine
Synonyms Avinza; Kadian; Morphine Sulfate; Depodur; Astramorph Pf; Duramorph Pf; Infumorph; Ms Contin; Oramorph Sr
Indication
Disease Entry ICD 11 Status REF
Chronic pain MG30 Approved [1]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 285.34
Topological Polar Surface Area (xlogp) 0.8
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 78% [3]
Clearance
The clearance of drug is 1600 mL/min [4]
Elimination
70-80% of an administered dose is excreted within 48 hours [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [6]
Metabolism
The drug is metabolized via the glucuronidation by UGT2B7 and sulfation at positions 3 and 6 [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.85255 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.65% [9]
Vd
The volume of distribution (Vd) of drug is 5.31 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 57.14 mg/mL [2]
Chemical Identifiers
Formula
C17H19NO3
IUPAC Name
(4R,4aR,7S,7aR,12bS)-3-methyl-2,4,4a,7,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
Canonical SMILES
CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O
InChI
InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1
InChIKey
BQJCRHHNABKAKU-KBQPJGBKSA-N
Cross-matching ID
PubChem CID
5288826
ChEBI ID
CHEBI:17303
CAS Number
57-27-2
DrugBank ID
DB00295
TTD ID
D0WE3O
VARIDT ID
DR00467
INTEDE ID
DR1112
ACDINA ID
D00447

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Modulator [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 3 (ABCC3) DTQ3ZHF MRP3_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [13]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [14]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [15]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [16]
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [17]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [18]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic pain
ICD Disease Classification MG30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Opioid receptor mu (MOP) DTT OPRM1 5.94E-01 -0.02 -0.17
P-glycoprotein 1 (ABCB1) DTP P-GP 7.83E-01 4.69E-02 1.89E-01
Multidrug resistance-associated protein 3 (ABCC3) DTP MRP3 8.71E-01 1.90E-02 1.26E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 3.17E-01 -6.95E-02 -2.88E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 6.06E-01 -2.42E-02 -1.64E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Morphine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Morphine and Dihydrocodeine. Chronic pain [MG30] [91]
Levomilnacipran DMV26S8 Moderate Additive serotonergic effects by the combination of Morphine and Levomilnacipran. Chronic pain [MG30] [92]
Coadministration of a Drug Treating the Disease Different from Morphine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Morphine caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [93]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Morphine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [94]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Morphine and Oliceridine. Acute pain [MG31] [95]
Chlorzoxazone DMCYVDT Major Additive CNS depression effects by the combination of Morphine and Chlorzoxazone. Acute pain [MG31] [95]
Scopolamine DMOM8AL Moderate Additive CNS depression effects by the combination of Morphine and Scopolamine. Addictive disorder [6C50-6C5Z] [96]
Buspirone DMBS632 Major Additive CNS depression effects by the combination of Morphine and Buspirone. Anxiety disorder [6B00-6B0Z] [95]
Clorazepate DMC3JST Major Additive CNS depression effects by the combination of Morphine and Clorazepate. Anxiety disorder [6B00-6B0Z] [91]
Alprazolam DMC7XDN Major Additive CNS depression effects by the combination of Morphine and Alprazolam. Anxiety disorder [6B00-6B0Z] [95]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Morphine and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [91]
Hydroxyzine DMF8Y74 Major Additive CNS depression effects by the combination of Morphine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [95]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Morphine and Halazepam. Anxiety disorder [6B00-6B0Z] [95]
Chlordiazepoxide DMTN5XI Major Additive CNS depression effects by the combination of Morphine and Chlordiazepoxide. Anxiety disorder [6B00-6B0Z] [95]
Chlormezanone DMTWUXR Major Additive CNS depression effects by the combination of Morphine and Chlormezanone. Anxiety disorder [6B00-6B0Z] [95]
Clobazam - Lundbeck DMW1OQ0 Major Additive CNS depression effects by the combination of Morphine and Clobazam - Lundbeck. Anxiety disorder [6B00-6B0Z] [95]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Morphine and Oxazepam. Anxiety disorder [6B00-6B0Z] [95]
Promazine DMZAL7W Major Additive CNS depression effects by the combination of Morphine and Promazine. Appearance/behaviour symptom [MB23] [95]
Desipramine DMT2FDC Moderate Additive CNS depression effects by the combination of Morphine and Desipramine. Attention deficit hyperactivity disorder [6A05] [92]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Morphine and Linezolid. Bacterial infection [1A00-1C4Z] [97]
Cariprazine DMJYDVK Major Additive CNS depression effects by the combination of Morphine and Cariprazine. Bipolar disorder [6A60] [95]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Morphine and Loperamide. Bowel habit change [ME05] [93]
Secobarbital DM14RF5 Major Additive CNS depression effects by the combination of Morphine and Secobarbital. Chronic insomnia [7A00] [95]
PF-04449913 DMSB068 Moderate Decreased clearance of Morphine due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [93]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Morphine and Olopatadine. Conjunctiva disorder [9A60] [98]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Morphine and Propofol. Corneal disease [9A76-9A78] [99]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Morphine and Methadone. Cough [MD12] [95]
Dextromethorphan DMUDJZM Moderate Additive CNS depression effects by the combination of Morphine and Dextromethorphan. Cough [MD12] [92]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Morphine and Ethanol. Cystitis [GC00] [100]
Sertraline DM0FB1J Moderate Additive serotonergic effects by the combination of Morphine and Sertraline. Depression [6A70-6A7Z] [92]
Trimipramine DM1SC8M Moderate Additive serotonergic effects by the combination of Morphine and Trimipramine. Depression [6A70-6A7Z] [92]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Morphine and Cyclobenzaprine. Depression [6A70-6A7Z] [95]
Imipramine DM2NUH3 Moderate Additive serotonergic effects by the combination of Morphine and Imipramine. Depression [6A70-6A7Z] [92]
Fluoxetine DM3PD2C Moderate Additive CNS depression effects by the combination of Morphine and Fluoxetine. Depression [6A70-6A7Z] [92]
Nortriptyline DM4KDYJ Moderate Additive serotonergic effects by the combination of Morphine and Nortriptyline. Depression [6A70-6A7Z] [92]
Vilazodone DM4LECQ Moderate Additive serotonergic effects by the combination of Morphine and Vilazodone. Depression [6A70-6A7Z] [92]
Nefazodone DM4ZS8M Moderate Additive serotonergic effects by the combination of Morphine and Nefazodone. Depression [6A70-6A7Z] [92]
Paroxetine DM5PVQE Moderate Additive serotonergic effects by the combination of Morphine and Paroxetine. Depression [6A70-6A7Z] [92]
Selegiline DM6034S Moderate Additive CNS depression effects by the combination of Morphine and Selegiline. Depression [6A70-6A7Z] [97]
Vortioxetine DM6F1PU Moderate Additive serotonergic effects by the combination of Morphine and Vortioxetine. Depression [6A70-6A7Z] [92]
Duloxetine DM9BI7M Moderate Additive CNS depression effects by the combination of Morphine and Duloxetine. Depression [6A70-6A7Z] [92]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Morphine and Isocarboxazid. Depression [6A70-6A7Z] [97]
Milnacipran DMBFE74 Moderate Additive serotonergic effects by the combination of Morphine and Milnacipran. Depression [6A70-6A7Z] [92]
Escitalopram DMFK9HG Moderate Additive CNS depression effects by the combination of Morphine and Escitalopram. Depression [6A70-6A7Z] [92]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Morphine and Tranylcypromine. Depression [6A70-6A7Z] [97]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Morphine and Desvenlafaxine. Depression [6A70-6A7Z] [92]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Morphine and OPC-34712. Depression [6A70-6A7Z] [95]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Morphine and Phenelzine. Depression [6A70-6A7Z] [97]
Clomipramine DMINRKW Moderate Additive CNS depression effects by the combination of Morphine and Clomipramine. Depression [6A70-6A7Z] [92]
Trazodone DMK1GBJ Moderate Additive serotonergic effects by the combination of Morphine and Trazodone. Depression [6A70-6A7Z] [92]
Amitriptyline DMK7F9S Moderate Additive CNS depression effects by the combination of Morphine and Amitriptyline. Depression [6A70-6A7Z] [92]
Amoxapine DMKITQE Moderate Additive CNS depression effects by the combination of Morphine and Amoxapine. Depression [6A70-6A7Z] [92]
Mirtazapine DML53ZJ Moderate Additive serotonergic effects by the combination of Morphine and Mirtazapine. Depression [6A70-6A7Z] [92]
Protriptyline DMNHTZI Moderate Additive serotonergic effects by the combination of Morphine and Protriptyline. Depression [6A70-6A7Z] [92]
Doxepin DMPI98T Moderate Additive CNS depression effects by the combination of Morphine and Doxepin. Depression [6A70-6A7Z] [92]
Maprotiline DMPWB7T Moderate Additive serotonergic effects by the combination of Morphine and Maprotiline. Depression [6A70-6A7Z] [92]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Morphine and Esketamine. Depression [6A70-6A7Z] [94]
Hyoscyamine DM804UR Moderate Additive CNS depression effects by the combination of Morphine and Hyoscyamine. Digestive system disease [DE2Z] [101]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Morphine and Mepenzolate. Digestive system disease [DE2Z] [96]
5-hydroxy-L-tryptophan DMDWZGJ Moderate Additive serotonergic effects by the combination of Morphine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [92]
Oxybutynine DMJPBAX Moderate Additive antimotility effects by the combination of Morphine and Oxybutynine. Discovery agent [N.A.] [96]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Morphine and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [91]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Morphine and Trihexyphenidyl. Dystonic disorder [8A02] [102]
Fenfluramine DM0762O Moderate Additive CNS depression effects by the combination of Morphine and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [92]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Morphine and Diazepam. Epilepsy/seizure [8A61-8A6Z] [95]
Primidone DM0WX6I Major Additive CNS depression effects by the combination of Morphine and Primidone. Epilepsy/seizure [8A61-8A6Z] [95]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Morphine and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [103]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Morphine and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [95]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Morphine and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [95]
Dantrolene DM1D8XY Major Additive CNS depression effects by the combination of Morphine and Dantrolene. Fever [MG26] [95]
Solifenacin DMG592Q Moderate Additive antimotility effects by the combination of Morphine and Solifenacin. Functional bladder disorder [GC50] [96]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Morphine and Tolterodine. Functional bladder disorder [GC50] [96]
Darifenacin DMWXLYZ Moderate Additive antimotility effects by the combination of Morphine and Darifenacin. Functional bladder disorder [GC50] [96]
Terbinafine DMI6HUW Moderate Decreased metabolism of Morphine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [104]
Propantheline DM2EN6G Moderate Additive antimotility effects by the combination of Morphine and Propantheline. Gastric ulcer [DA60] [96]
Cisapride DMY7PED Minor Altered absorption of Morphine due to GI dynamics variation caused by Cisapride. Gastro-oesophageal reflux disease [DA22] [105]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Morphine and Brimonidine. Glaucoma [9C61] [106]
Rifampin DMA8J1G Moderate Increased metabolism of Morphine caused by Rifampin. HIV-infected patients with tuberculosis [1B10-1B14] [107]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Morphine and Procarbazine. Hodgkin lymphoma [2B30] [97]
Belladonna DM2RBWK Moderate Additive antimotility effects by the combination of Morphine and Belladonna. Infectious gastroenteritis/colitis [1A40] [96]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Morphine and Suvorexant. Insomnia [7A00-7A0Z] [95]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Morphine and Amobarbital. Insomnia [7A00-7A0Z] [95]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Morphine and Ramelteon. Insomnia [7A00-7A0Z] [95]
Eszopiclone DM8RZ9H Major Additive CNS depression effects by the combination of Morphine and Eszopiclone. Insomnia [7A00-7A0Z] [95]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Morphine and Flurazepam. Insomnia [7A00-7A0Z] [95]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Morphine and Triazolam. Insomnia [7A00-7A0Z] [95]
Pentobarbital DMFNH7L Major Additive CNS depression effects by the combination of Morphine and Pentobarbital. Insomnia [7A00-7A0Z] [95]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Morphine and Zaleplon. Insomnia [7A00-7A0Z] [95]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Morphine and Propiomazine. Insomnia [7A00-7A0Z] [95]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Morphine and Tasimelteon. Insomnia [7A00-7A0Z] [95]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Morphine and Paraldehyde. Insomnia [7A00-7A0Z] [95]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Morphine and ITI-007. Insomnia [7A00-7A0Z] [95]
Zolpidem DMWOSKJ Major Additive CNS depression effects by the combination of Morphine and Zolpidem. Insomnia [7A00-7A0Z] [95]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Morphine and Quazepam. Insomnia [7A00-7A0Z] [95]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Morphine and Estazolam. Insomnia [7A00-7A0Z] [95]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Morphine and Polyethylene glycol. Irritable bowel syndrome [DD91] [108]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Morphine and Clidinium. Irritable bowel syndrome [DD91] [96]
Dicyclomine DMZSDGX Moderate Additive antimotility effects by the combination of Morphine and Dicyclomine. Irritable bowel syndrome [DD91] [96]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Morphine and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [95]
Lumefantrine DM29GAD Moderate Decreased metabolism of Morphine caused by Lumefantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [94]
Meprobamate DMHM93Y Major Additive CNS depression effects by the combination of Morphine and Meprobamate. Malaria [1F40-1F45] [95]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Morphine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [109]
Zolmitriptan DM1IB4Q Moderate Additive serotonergic effects by the combination of Morphine and Zolmitriptan. Migraine [8A80] [92]
Almogran DM7I64Z Moderate Additive CNS depression effects by the combination of Morphine and Almogran. Migraine [8A80] [92]
Frovatriptan DM7RE8P Moderate Additive CNS depression effects by the combination of Morphine and Frovatriptan. Migraine [8A80] [92]
Rizatriptan DMDJMA3 Moderate Additive serotonergic effects by the combination of Morphine and Rizatriptan. Migraine [8A80] [92]
Naratriptan DMO50U2 Moderate Additive serotonergic effects by the combination of Morphine and Naratriptan. Migraine [8A80] [92]
Sumatriptan DMVYXR8 Moderate Additive serotonergic effects by the combination of Morphine and Sumatriptan. Migraine [8A80] [92]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Morphine and Lasmiditan. Migraine [8A80] [110]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Morphine and Flibanserin. Mood disorder [6A60-6E23] [111]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Morphine and Thalidomide. Multiple myeloma [2A83] [112]
Carisoprodol DMWR1JC Major Additive CNS depression effects by the combination of Morphine and Carisoprodol. Musculoskeletal disorder [FA00-FC0Z] [95]
Rifabutin DM1YBHK Moderate Increased metabolism of Morphine caused by Rifabutin. Mycobacterium infection [1B10-1B21] [107]
Imatinib DM7RJXL Moderate Decreased metabolism of Morphine caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [113]
Prasugrel DM7MT6E Moderate Altered absorption of Morphine due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [114]
Droperidol DM0DXA8 Major Additive cardiorespiratory depression effects by the combination of Morphine and Droperidol. Nausea/vomiting [MD90] [115]
Palonosetron DMBHMOX Moderate Additive serotonergic effects by the combination of Morphine and Palonosetron. Nausea/vomiting [MD90] [92]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Morphine when combined with Metoclopramide. Nausea/vomiting [MD90] [116]
Granisetron DMIUW25 Moderate Additive CNS depression effects by the combination of Morphine and Granisetron. Nausea/vomiting [MD90] [92]
Dolasetron DMMG26Z Moderate Additive CNS depression effects by the combination of Morphine and Dolasetron. Nausea/vomiting [MD90] [92]
Ondansetron DMOTQ1I Moderate Additive serotonergic effects by the combination of Morphine and Ondansetron. Nausea/vomiting [MD90] [92]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Morphine and Bupropion. Nicotine use disorder [6C4A] [117]
Sibutramine DMFJTDI Moderate Additive serotonergic effects by the combination of Morphine and Sibutramine. Obesity [5B80-5B81] [92]
Dexfenfluramine DMJ7YDS Moderate Additive serotonergic effects by the combination of Morphine and Dexfenfluramine. Obesity [5B80-5B81] [92]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Morphine and Levomethadyl Acetate. Opioid use disorder [6C43] [91]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Morphine and Apraclonidine. Optic nerve disorder [9C40] [106]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Morphine and Pentazocine. Pain [MG30-MG3Z] [118]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Morphine and Dextropropoxyphene. Pain [MG30-MG3Z] [119]
Butorphanol DM5KYPJ Major Additive hypotensive effects by the combination of Morphine and Butorphanol. Pain [MG30-MG3Z] [118]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Morphine and Oxymorphone. Pain [MG30-MG3Z] [95]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Morphine and Levorphanol. Pain [MG30-MG3Z] [95]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Morphine and Hydromorphone. Pain [MG30-MG3Z] [95]
Dezocine DMJDB0Y Major Additive hypotensive effects by the combination of Morphine and Dezocine. Pain [MG30-MG3Z] [118]
Codeine DMJX6ZG Major Additive CNS depression effects by the combination of Morphine and Codeine. Pain [MG30-MG3Z] [95]
Flavoxate DMKV4NL Moderate Additive antimotility effects by the combination of Morphine and Flavoxate. Pain [MG30-MG3Z] [96]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Morphine and Nalbuphine. Pain [MG30-MG3Z] [118]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Morphine and Buprenorphine. Pain [MG30-MG3Z] [118]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Morphine and Hydrocodone. Pain [MG30-MG3Z] [95]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Morphine and Meperidine. Pain [MG30-MG3Z] [95]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Morphine and Oxycodone. Pain [MG30-MG3Z] [95]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Morphine and Biperiden. Parkinsonism [8A00] [102]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Morphine and Procyclidine. Parkinsonism [8A00] [102]
Pimavanserin DMR7IVC Major Additive CNS depression effects by the combination of Morphine and Pimavanserin. Parkinsonism [8A00] [95]
Orphenadrine DMW542E Major Additive CNS depression effects by the combination of Morphine and Orphenadrine. Parkinsonism [8A00] [95]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Morphine and Lindane. Pediculosis [1G00] [120]
Methylscopolamine DM5VWOB Moderate Additive CNS depression effects by the combination of Morphine and Methylscopolamine. Peptic ulcer [DA61] [96]
Fluphenazine DMIT8LX Major Additive CNS depression effects by the combination of Morphine and Fluphenazine. Psychotic disorder [6A20-6A25] [121]
Triflupromazine DMKFQJP Major Additive CNS depression effects by the combination of Morphine and Triflupromazine. Psychotic disorder [6A20-6A25] [95]
Celecoxib DM6LOQU Moderate Decreased metabolism of Morphine caused by Celecoxib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [122]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Morphine and Quetiapine. Schizophrenia [6A20] [121]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Morphine and Mesoridazine. Schizophrenia [6A20] [121]
Thioridazine DM35M8J Major Additive CNS depression effects by the combination of Morphine and Thioridazine. Schizophrenia [6A20] [95]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Morphine and Aripiprazole. Schizophrenia [6A20] [95]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Morphine and Iloperidone. Schizophrenia [6A20] [95]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Morphine and Paliperidone. Schizophrenia [6A20] [95]
Loxapine DM8AI9U Major Additive CNS depression effects by the combination of Morphine and Loxapine. Schizophrenia [6A20] [121]
Haloperidol DM96SE0 Major Additive CNS depression effects by the combination of Morphine and Haloperidol. Schizophrenia [6A20] [95]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Morphine and Perphenazine. Schizophrenia [6A20] [95]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Morphine and Molindone. Schizophrenia [6A20] [95]
Chlorpromazine DMBGZI3 Major Additive CNS depression effects by the combination of Morphine and Chlorpromazine. Schizophrenia [6A20] [121]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Morphine and Thiothixene. Schizophrenia [6A20] [121]
Clozapine DMFC71L Major Additive CNS depression effects by the combination of Morphine and Clozapine. Schizophrenia [6A20] [121]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Morphine and Trifluoperazine. Schizophrenia [6A20] [95]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Morphine and Risperidone. Schizophrenia [6A20] [95]
Olanzapine DMPFN6Y Major Additive CNS depression effects by the combination of Morphine and Olanzapine. Schizophrenia [6A20] [121]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Morphine and Asenapine. Schizophrenia [6A20] [95]
Pimozide DMW83TP Major Additive CNS depression effects by the combination of Morphine and Pimozide. Schizophrenia [6A20] [95]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Morphine and Fentanyl. Sensation disturbance [MB40] [95]
Pitolisant DM8RFNJ Moderate Increased metabolism of Morphine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [93]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Morphine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [123]
Brilinta DMBR01X Moderate Altered absorption of Morphine due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [114]
Clopidogrel DMOL54H Moderate Altered absorption of Morphine due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [114]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Morphine and Tizanidine. Tonus and reflex abnormality [MB47] [95]
Atropine DMEN6X7 Moderate Additive antimotility effects by the combination of Morphine and Atropine. Unspecific substance harmful effect [NE6Z] [96]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Morphine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [124]
Mexiletine DMCTE9R Moderate Altered absorption of Morphine due to GI dynamics variation caused by Mexiletine. Ventricular tachyarrhythmia [BC71] [115]
⏷ Show the Full List of 174 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Butylated hydroxytoluene E00336 31404 Antioxidant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 30 E00456 3000709 Colorant
Diethyl phthalate E00135 6781 Plasticizing agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Fumaric acid E00420 444972 Acidulant; Antioxidant; Complexing agent; Flavoring agent; Solubilizing agent
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Butylhydroxyanisole E00308 24667 Antimicrobial preservative; Antioxidant
Cetostearyl alcohol E00353 62238 Emollient; Emulsifying agent; Viscosity-controlling agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA E00607 135423095 Colorant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 46 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Morphine 15 mg tablet 15 mg 12 HR Extended Release Oral Tablet Oral
Morphine 200 mg tablet 200 mg 12 HR Extended Release Oral Tablet Oral
Morphine 60 mg tablet 60 mg 12 HR Extended Release Oral Tablet Oral
Morphine 130 mg capsule 130 mg Extended Release Oral Capsule Oral
Morphine 40 mg capsule 40 mg Extended Release Oral Capsule Oral
Morphine 70 mg capsule 70 mg Extended Release Oral Capsule Oral
Morphine 30 mg tablet 30 mg 12 HR Extended Release Oral Tablet Oral
Morphine 80 mg capsule 80 mg Extended Release Oral Capsule Oral
Morphine 150 mg capsule 150 mg Extended Release Oral Capsule Oral
Morphine 10 mg capsule 10 mg Extended Release Oral Capsule Oral
Morphine 100 mg tablet 100 mg 12 HR Extended Release Oral Tablet Oral
Morphine 30 mg capsule 30 mg Extended Release Oral Capsule Oral
Morphine 45 mg capsule 45 mg 24 HR Extended Release Oral Capsule Oral
Morphine 200 mg tablet 200 mg Extended Release Oral Tablet Oral
Morphine 30 mg tablet 30 mg Extended Release Oral Tablet Oral
Morphine 90 mg capsule 90 mg 24 HR Extended Release Oral Capsule Oral
Morphine 100 mg capsule 100 mg Extended Release Oral Capsule Oral
Morphine 120 mg capsule 120 mg 24 HR Extended Release Oral Capsule Oral
Morphine 30 mg capsule 30 mg 24 HR Extended Release Oral Capsule Oral
Morphine 50 mg capsule 50 mg Extended Release Oral Capsule Oral
Morphine 60 mg capsule 60 mg 24 HR Extended Release Oral Capsule Oral
Morphine 60 mg capsule 60 mg Extended Release Oral Capsule Oral
Morphine 200 mg capsule 200 mg Extended Release Oral Capsule Oral
Morphine 100 mg tablet 100 mg Extended Release Oral Tablet Oral
Morphine 15 mg tablet 15 mg Extended Release Oral Tablet Oral
Morphine 75 mg capsule 75 mg 24 HR Extended Release Oral Capsule Oral
Morphine 20 mg capsule 20 mg Extended Release Oral Capsule Oral
Morphine 60 mg tablet 60 mg Extended Release Oral Tablet Oral
Morphine 15 mg tablet 15 mg Oral Tablet Oral
Morphine 30 mg tablet 30 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Paladin Labs - Product Monograph: SANDOMIGRAN (Pizotifen hydrogen malate 0.5 mg and 1 mg tablets)
4 Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML: The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol. 2000 Mar;49(3):207-14.
5 Hoskin PJ, Hanks GW: Morphine: pharmacokinetics and clinical practice. Br J Cancer. 1990 Nov;62(5):705-7.
6 Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103. doi: 10.1016/j.jpainsymman.2005.01.012.
7 Somani SM, Roberts JB, Wilson A: Pyridostigmine metabolism in man. Clin Pharmacol Ther. 1972 May-Jun;13(3):393-9. doi: 10.1002/cpt1972133393.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
11 Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. 2007 Feb;453(5):661-73.
12 Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005 Aug;49(7):902-8.
13 Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull. 2005 Oct;28(10):2026-7.
14 Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54.
15 Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos. 2008 Apr;36(4):688-94.
16 In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
17 Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine. Drug Metab Dispos. 2010 Apr;38(4):545-53.
18 Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
19 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
20 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
21 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
22 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
25 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
26 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
27 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
28 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
29 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
30 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
31 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
32 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
33 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
34 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
35 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
36 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
37 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
38 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
39 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
40 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
41 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
42 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
43 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
44 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
45 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
46 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
47 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
48 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
49 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
50 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
51 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
52 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
53 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
54 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
55 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
56 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
57 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
58 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
59 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
60 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
61 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
62 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
63 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
64 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
65 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
66 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
67 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
68 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
69 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
70 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
71 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
72 Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry. 2003 May 13;42(18):5429-37.
73 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
74 ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44.
75 Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30.
76 Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702.
77 Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta. 2006 Nov-Dec;27(11-12):1096-102.
78 Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21.
79 Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7.
80 Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
81 Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50.
82 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
83 Clinical pipeline report, company report or official report of signaturerx.
84 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
85 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
86 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
87 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
88 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
89 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
91 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
92 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
93 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
94 Cerner Multum, Inc. "Australian Product Information.".
95 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
96 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
97 Evans-Prosser CD "The use of pethidine and morphine in the presence of monoamine oxidase inhibitors." Br J Anaesth 40 (1968): 279-82. [PMID: 5654977]
98 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
99 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
100 Product Information. Avinza (morphine). Ligand Pharmaceuticals, San Diego, CA.
101 Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
102 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
103 Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
104 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
105 Greiff JMC, Rowbotham D "Pharmacokinetic drug interactions with gastrointestinal motility modifying agents." Clin Pharmacokinet 27 (1994): 447-61. [PMID: 7882635]
106 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
107 Fromm MF, Eckhardt K, Li SX, Schanzle G, Hofmann U, Mikus G, Eichelbaum M "Loss of analgesic effect of morphine due to coadministration of rifampin." Pain 72 (1997): 261-7. [PMID: 9272811]
108 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
109 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
110 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
111 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
112 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
113 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
114 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
115 Canadian Pharmacists Association.
116 Product Information. Reglan (metoclopramide). Wyeth-Ayerst Laboratories, Philadelphia, PA.
117 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
118 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
119 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
120 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
121 Cerner Multum, Inc. "Canadian Product Information.".
122 Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
123 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
124 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.